Search Results

Clarity Pharmaceuticals and PSI CRO AG have entered into an agreement and have commenced work towards Clarity’s Phase III diagnostic trial of SAR-bisPSMA in prostate cancer participants, CLARIFY 1.

Enovis Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System) for use with the Company’s STAR® total ankle replacement system.

Masimo (NASDAQ: MASI) today announced the findings of a study published in Frontiers in Neuroscience in which Dr. Lichy Han and colleagues at Stanford University evaluated the ability of Masimo SedLine® brain function monitoring to assess the sedation levels of patients undergoing drug-induced sleep endoscopy (DISE) with dexmedetomidine – a sedative with numerous advantages.

TruTag Technologies, Inc. and Spinnaker Biosciences, Inc. today announced that they have entered into a strategic supply partnership for TruTag’s advanced nano-porous silica (pSi) particles to support the commercialization of Spinnaker’s new therapy for the treatment of age-related macular degeneration (AMD).

ITM Isotope Technologies Munich SE announced that it has entered into a co-development and exclusive license agreement with the Paul Scherrer Institute, a leading Swiss research institute in the natural and engineering sciences, for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161.

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials of its psilocybin to address treatment-resistant depression.

Teleflex Incorporated (NYSE: TFX) continues to deliver COMPLETE confidence with the release of the Arrow® ErgoPack® Complete Multi-Lumen Access Catheter (MAC) System and the Arrow® ErgoPack® Complete Percutaneous Sheath Introducer (PSI) System.

Incannex Healthcare on Wednesday said its investigational psychedelic psilocybin met the primary endpoint, demonstrating it can reduce Hamilton anxiety scores by more than nine points versus placebo.

Masimo announced the findings of a prospective study published in Frontiers in Neurology in which Dr. Na Xu and colleagues at Capital Medical University in Beijing investigated whether general anesthesia guided by Masimo SedLine® Brain Function Monitoring parameters on Root® could reduce the incidence of postoperative delirium in patients undergoing carotid endarterectomy.